JUBILANT PHARMACEUTICALS: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
JUBILANT PHARMACEUTICALS
Largest movements
- Receivables within one year -€163,910
down €163,910 (-35.4%), from €463,158 to €299,248
of which Trade receivables: -€233,679
- Financial fixed assets +€8,504
up €8,504 (+2,835%), from €300 to €8,804
- Cash +€5,862
up €5,862 (+27.3%), from €21,509 to €27,370
mainly Receivables within one year (+€163,910) and Other debts (+€147,892)
- Profit (loss) carried forward -€239,918
down €239,918 (-12.1%), from -€2.0m to -€2.2m
- Other debts +€147,892
up €147,892 (+13.7%), from €1.1m to €1.2m
- Trade debts -€60,220
down €60,220 (-27.7%), from €217,028 to €156,808
- Turnover -€370,736
down €370,736 (-38.9%), from €953,015 to €582,278
- Goods and materials -€369,473
down €369,473 (-38.7%), from €953,518 to €584,044
- Financial income -€27,245
no longer reported in 2025 (was €27,245)
- Services and other goods +€24,016
up €24,016 (+11.0%), from €217,926 to €241,943
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €488,102 | €335,856 | -€152,247 | -31.2% |
| Fixed assets | 21/28 | €300 | €8,804 | +€8,504 | +2,835% |
| Financial fixed assets | 28 | €300 | €8,804 | +€8,504 | +2,835% |
| Other financial fixed assets | 284/8 | €300 | €8,804 | +€8,504 | +2,835% |
| Amounts receivable and cash guarantees | 285/8 | €300 | €8,804 | +€8,504 | +2,835% |
| Current assets | 29/58 | €487,802 | €327,051 | -€160,751 | -33.0% |
| Amounts receivable within one year | 40/41 | €463,158 | €299,248 | -€163,910 | -35.4% |
| Trade receivables | 40 | €450,385 | €216,706 | -€233,679 | -51.9% |
| Other amounts receivable | 41 | €12,773 | €82,542 | +€69,769 | +546% |
| Cash at bank and in hand | 54/58 | €21,509 | €27,370 | +€5,862 | +27.3% |
| Deferred charges and accrued income | 490/1 | €3,135 | €433 | -€2,702 | -86.2% |
| Total equity and liabilities | 10/49 | €488,102 | €335,856 | -€152,247 | -31.2% |
| Equity | 10/15 | -€806,548 | -€1,046,466 | -€239,918 | -29.7% |
| Contributions | 10/11 | €1,050,300 | €1,050,300 | = | 0.0% |
| Capital | 10 | €1,050,300 | €1,050,300 | = | 0.0% |
| Issued capital | 100 | €1,050,300 | €1,050,300 | = | 0.0% |
| Reserves | 13 | €126,742 | €126,742 | = | 0.0% |
| Non-distributable reserves | 130/1 | €85,443 | €85,443 | = | 0.0% |
| Legal reserve | 130 | €82,698 | €82,698 | = | 0.0% |
| Reserves not available under the articles | 1311 | €2,745 | €2,745 | = | 0.0% |
| Distributable reserves | 133 | €41,299 | €41,299 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€1,983,590 | -€2,223,508 | -€239,918 | -12.1% |
| Amounts payable | 17/49 | €1,294,650 | €1,382,322 | +€87,672 | +6.8% |
| Amounts payable within one year | 42/48 | €1,294,650 | €1,382,322 | +€87,672 | +6.8% |
| Trade debts | 44 | €217,028 | €156,808 | -€60,220 | -27.7% |
| Suppliers | 440/4 | €217,028 | €156,808 | -€60,220 | -27.7% |
| Other amounts payable | 47/48 | €1,077,622 | €1,225,514 | +€147,892 | +13.7% |
| Operating income | 70/76A | €994,867 | €620,124 | -€374,743 | -37.7% |
| Turnover | 70 | €953,015 | €582,278 | -€370,736 | -38.9% |
| Other operating income | 74 | €41,853 | €37,846 | -€4,007 | -9.6% |
| Operating charges | 60/66A | €1,174,532 | €827,338 | -€347,193 | -29.6% |
| Goods for resale, raw materials and consumables | 60 | €953,518 | €584,044 | -€369,473 | -38.7% |
| Purchases | 600/8 | €953,518 | €584,044 | -€369,473 | -38.7% |
| Services and other goods | 61 | €217,926 | €241,943 | +€24,016 | +11.0% |
| Remuneration, social security and pensions | 62 | €706 | €902 | +€196 | +27.8% |
| Other operating charges | 640/8 | €2,382 | €449 | -€1,933 | -81.2% |
| Operating profit (loss) | 9901 | -€179,664 | -€207,214 | -€27,549 | -15.3% |
| Financial income | 75/76B | €27,245 | - | -€27,245 | |
| Recurring financial income | 75 | €27,245 | - | -€27,245 | |
| Other financial income | 752/9 | €27,245 | - | -€27,245 | |
| Financial charges | 65/66B | €28,139 | €32,705 | +€4,566 | +16.2% |
| Recurring financial charges | 65 | €28,139 | €32,705 | +€4,566 | +16.2% |
| Other financial charges | 652/9 | €28,139 | €32,705 | +€4,566 | +16.2% |
| Profit (loss) for the period before taxes | 9903 | -€180,559 | -€239,918 | -€59,360 | -32.9% |
| Profit (loss) for the period | 9904 | -€180,559 | -€239,918 | -€59,360 | -32.9% |
| Profit (loss) for the period to be appropriated | 9905 | -€180,559 | -€239,918 | -€59,360 | -32.9% |
Source: filed annual accounts (NBB), financial years ended 31 March 2024 and 31 March 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.